Inclusion Criteria:

- Understand and voluntarily sign an informed consent form

- Patients willing and able to undergo autologous and allogeneic transplantation

- no previous systemic therapy for the treatment of multiple myeloma (dexamethasone at
a cumulative dose of 320 mg; plasmapheresis/dialysis without concomitant
chemotherapy, local irradiation of bone lesions; and surgical intervention is
accepted as pretreatment)

- Newly diagnosed multiple myeloma according to common diagnostic criteria including
presence of CRAB and measurable disease parameters

- Cardiac ejection fraction (LVEF) of at least 50%

- Corrected DLCO of at least 50% ; alternatively pO2 [art.] of at least 70mmHg

- Karnofsky performance status of greater or equal to 50%

- adequate bone marrow function

- adequate serum chemistry values

- Use of adequate contraception for female subjects with childbearing potential and
male subjects

- Bone marrow sample available for analysis of molecular cytogenetics

- Able to administer low molecular-weight heparin as a prophylactic anticoagulation
therapy for the first three months(applicable for subjects randomized to RAD) and
able to administer ASS 100 mg/d (applicable for subjects randomized to VRD)

Exclusion Criteria:

- Any serious medical condition, laboratory abnormality, or psychiatric illness that
would prevent the subject from signing the informed consent form

- Pregnant or lactating females

- Any condition, including the presence of laboratory abnormalities, which places the
subject at unacceptable risk

- History of myocardial infarction; NYHA Class III or IV heart failure, uncontrolled
angina, severe uncontrolled ventricular arrhythmias; concomitant pericarditis or
peri-/myocarditis

- Use of any other experimental drug or therapy within 28 days of baseline

- Greater or equal to Grade 2 peripheral neuropathy on clinical examination within 14
days before enrollment

- Known intolerance of boron

- Hypersensitivity to acyclovir or similar anti-viral drug

- Prior malignancy except adequately treated basal cell or squamous cell skin cancer,
in situ cervical, breast or prostate cancer

- HIV positive, active hepatitis B, C or D viral infection, known CMV
reactivation/active infection, EBV reactivation/active infection or treponema
pallidum infection

- Uncontrolled diabetes mellitus

- Non-secretory MM

- Clinically relevant active infection or serious co-morbid medical conditions